Learn more about our Diagnostics work.
WASHINGTON, D.C. – AdvaMed® President and CEO Scott Whitaker released the following statement: “AdvaMed® fully supports policies that foster innovation and regulatory flexibility to speed quality tests to patients. This principle…
WASHINGTON, D.C. – AdvaMed® President and CEO Scott Whitaker released the following statement:
Read background information on how AdvaMedDx®’s members produce IVD tests to detect COVID-19.
WASHINGTON, D.C. – The Advanced Medical Technology Association® (AdvaMed®) today announced that total U.S. shipments of COVID-19 molecular diagnostic tests reached approximately 100 million, as of July 25, based on the latest…
Unequal access to medical technologies and, more broadly, health care services continues to persist – often disproportionately impacting the lives of racial and ethnic minorities.
AdvaMed® announced that shipments of COVID-19 molecular diagnostic tests reached one million per day for the week ending July 24, based on the latest data from the association’s National Testing Registry.
Whitaker Calls National Registry “Crucial Tool” for Federal, State Authorities; Announces More Than 65 Million Tests Shipped Nationwide Since Beginning of Pandemic WASHINGTON, D.C. – In its latest action to help ensure…
WASHINGTON, D.C. – The Advanced Medical Technology Association® (AdvaMed®) today released the following statement from Susan Van Meter, executive director of AdvaMedDx®, in response to comments on COVID-19 serology/antibody testing at today’s hearing…
AdvaMedDx® developed the VALID Assessment Framework as a tool to analyze the legislation.
Doctors, nurses and health care providers fighting on the front lines against the coronavirus are modern-day heroes. Every day they selflessly risk their own health to provide essential care to…